A clinical trial to look at the effects of gantenerumab on the body in people with early Alzheimer’s disease
A phase II, multicenter, open-label, single arm study to evaluate the pharmacodynamic effects of once weekly administration of gantenerumab in participants with early (prodromal to mild) Alzheimer’s disease
Neurodegenerative Disorder Alzheimer's Disease (AD)
For the latest version of this information please go to www.forpatients.roche.com